Nuala Moran

Biotechnology and risk have always been synonymous. But now those risks are evolving and growing, exposing companies to fresh hazards.

A new approach to collaboration in research sounds like it would serve Europe well. And, Nuala Moran discovers, the model is being pioneered by a European company.

R&D Commissioner Janez Potočnik is keen to see his country, Slovenia, advancing the European Research Area during its EU Presidency. But, asks Nuala Moran, is the necessary momentum there?

The Commission is formulating its strategy on cluster development to boost innovation and maximise returns from structural funds and related budgets. But is there a policy recipe for a perfectly formed cluster?

The Internet has unleashed waves of innovation – from online banking to virtual drug discovery. But it has also spawned the rise of organised cybercrime.

The university has breathed new life into what most thought an extinct species – the venture capitalist-run seed fund.

UK biotech Phynova makes a business out of developing traditional medicines, but when it comes to raising money it is pioneering a new, low-cost route to American investors.

Financing high-tech start-ups is not getting any easier, but a pioneering UK biotech may have an escape route

One moment environmental poster child, the next grim reaper. It’s time to draw breath and plan for the appropriate, sustainable use of biofuels, says Science|Business’s Nuala Moran.

The Lisbon Strategy is working, but global financial instability means Europe needs to redouble its efforts in implementing reforms